Page 2 - Antipsychotics News Today

While antipsychotics can help manage certain mental health conditions, it is important to be aware of the risks associated with their use.

Black patients with schizophrenia are significantly less likely than White patients to be prescribed clozapine, new data showed.

Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics. The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. "Current antipsychotic treatments are associated with a number of adverse effects, including adverse metabolic profiles, increases in ...

Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative...

1. Patients in the KarXT (xanomeline–trospium) group reported a significant reduction in Positive and Negative Syndrome Scale (PANSS) score compared to those in the placebo group. 2. Majority of adverse events were mild-to-moderate, with no treatment-related fatalities or increase in extrapyramidal motor symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: Current antipsychotic therapies for schizophrenia

Patients with schizophrenia discharged on an LAI antipsychotic had significantly lower 30-day psychiatric readmission rates than those sent home with an oral antipsychotic.

Adults with resistant schizophrenia have significant gut microbiome differences vs their counterparts who respond to treatment, a new finding that may be driven by clozapine treatment.

Recent research highlighted the potential role of an atypical antipsychotic to treat anxiety — a prevalent and undertreated symptom in BPD that comes without the typical metabolic side effects.

Iloperidone, an atypical antipsychotic approved for schizophrenia, appears to be safe and effective in the treatment of bipolar mania, phase 3 results of an RCT showed.

The investigational antipsychotic KarXT is effective in reducing positive and negative symptoms of schizophrenia, with a favorable side-effect profile in the pivotal EMERGENT-2 trial.